Iodine deficiency as a side effect of administration of iodine-containing contrast agents. In some cases, excessive iodine contributes to a risk of autoimmune thyroid diseases (Hashimoto's thyroiditis and Graves' disease). Iodine deficiency resulting in goiter occurs 187 million people globally (2.7% of the population). Certain areas of the world, due to natural deficiency and unavailability of iodine, are severely affected by iodine deficiency, which affects approximately two billion people worldwide. It is particularly common in the Western Pacific, South-East Asia and Africa. Among other nations affected by iodine deficiency, China and Kazakhstan have begun taking action, while Russia has not. Successful campaigns
Iodine-125 Iodine-125 Iodine-125 (I) is a radioisotope of iodine which has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumors. It is the second longest-lived radioisotope of iodine, after iodine-129. Its half-life is 59.49 days and it decays by electron capture to an excited state of tellurium-125. This state is not the metastable Te-125m, but rather a lower energy state that decays immediately by gamma decay with a maximum energy of 35 keV. Some of the excess energy of the excited Te-125 may